Medical Care
Global Sexually Transmitted Diseases Diagnostics Market Outlook, In‑Depth Analysis & Forecast to 2031
- Nov 04, 25
- ID: 564542
- Pages: 134
- Figures: 131
- Views: 6
Report Includes:
This definitive report equips CEOs, marketing directors, and investors with a 360° view of the global Sexually Transmitted Diseases Diagnostics market across value chain. It analyzes historical revenue data (2020–2024) and delivers forecasts through 2031, illuminating demand trends and growth drivers.
By segmenting the market by Type and by Application, the study quantifies market size, growth rates, niche opportunities, and substitution risks, and analyzes downstream customers distribution pattern.
Granular regional insights cover five major markets—North America, Europe, APAC, South America, and MEA—with in‑depth analysis of 20+ countries, detailing dominant products, competitive landscape, and downstream demand trends.
Critical competitive intelligence profiles players—revenue, margins, pricing strategies, and major customers—and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths.
A concise Industry‑chain overview maps upstream, middlestream, and downstream distribution dynamics to identify strategic gaps and unmet demand.
Market Segmentation
By Company
Abbott
Thermo Fisher Scientific
CERTEST BIOTEC
OPERON
Roche
Bio-Rad laboratories
Qaigen
Diasorin SPA
MedMira
Hologic
Cepheid
BioMeriuex
Segment by Type
Cultural and Isolated Organisms
Molecular Test
Immunology Assay
Other
Segment by Application
Gonorrhea
Syphilis
Chlamydia
Herpes Simplex Virus
Human Papillomavirus
Others
Sales by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
Japan
South Korea
India
Australia
Vietnam
Indonesia
Malaysia
Philippines
Singapore
Rest of Asia
Europe
Germany
U.K.
France
Italy
Spain
Benelux
Russia
Rest of Europe
Central and South America
Brazil
Argentina
Rest of South America
Middle East & Africa
GCC Countries
Egypt
Israel
South Africa
Rest of MEA
Chapter Outline
Chapter 1: Defines the Sexually Transmitted Diseases Diagnostics study scope, segments the market by Type and by Application, etc, highlights segment size and growth potential.
Chapter 2: Offers current market state, projects global revenue and sales to 2031, pinpointing high consumption regions and emerging market catalysts
Chapter 3: Dissects the player landscape—ranks by revenue and profitability, details Player performance by product type and evaluates concentration alongside M&A moves.
Chapter 4: Unlocks high margin product segments—compares revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks
Chapter 5: Targets downstream market opportunities—evaluates market size by Application, identifies emerging use cases, and profiles leading customers by region and by Application.
Chapter 6: North America—breaks down market size by Type, by Application and country, profiles key players and assesses growth drivers and barriers.
Chapter 7: Europe—analyses regional market by Type, by Application and players, flagging drivers and barriers.
Chapter 8: Asia Pacific—quantifies market size by Type, by Application, and region/country, profiles top players, and uncovers high potential expansion areas.
Chapter 9: Central & South America—measures market size by Type, by Application, and country, profiles top players, and identifies investment opportunities and challenges.
Chapter 10: Middle East and Africa—evaluates market size by Type, by Application, and country, profiles key players, and outlines investment prospects and market hurdles
Chapter 11: Profiles players in depth—details product specs, revenue, margins; Top-tier players 2024 sales breakdowns by Product type, by Application, by region SWOT analysis, and recent strategic developments.
Chapter 12: Industry chain—analyses upstream, cost drivers, plus downstream channels.
Chapter 13: Market dynamics—explores drivers, restraints, regulatory impacts, and risk mitigation strategies.
Chapter 14: Actionable conclusions and strategic recommendations.
Why This Report:
Beyond standard market data, this analysis provides a clear profitability roadmap—empowering you to:
Allocate capital strategically to high growth regions (Chapters 6–10) and margin rich segments (Chapter 5).
Negotiate from strength with suppliers (Chapter 12) and customers (Chapter 5) using cost and demand intelligence.
Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 3 and 11).
Capitalize on the projected billion‑dollar opportunity with data‑driven regional and segment tactics (Chapter 12-14).
Leverage this 360° intelligence to turn market complexity into actionable competitive advantage.
This definitive report equips CEOs, marketing directors, and investors with a 360° view of the global Sexually Transmitted Diseases Diagnostics market across value chain. It analyzes historical revenue data (2020–2024) and delivers forecasts through 2031, illuminating demand trends and growth drivers.
By segmenting the market by Type and by Application, the study quantifies market size, growth rates, niche opportunities, and substitution risks, and analyzes downstream customers distribution pattern.
Granular regional insights cover five major markets—North America, Europe, APAC, South America, and MEA—with in‑depth analysis of 20+ countries, detailing dominant products, competitive landscape, and downstream demand trends.
Critical competitive intelligence profiles players—revenue, margins, pricing strategies, and major customers—and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths.
A concise Industry‑chain overview maps upstream, middlestream, and downstream distribution dynamics to identify strategic gaps and unmet demand.
Market Segmentation
By Company
Abbott
Thermo Fisher Scientific
CERTEST BIOTEC
OPERON
Roche
Bio-Rad laboratories
Qaigen
Diasorin SPA
MedMira
Hologic
Cepheid
BioMeriuex
Segment by Type
Cultural and Isolated Organisms
Molecular Test
Immunology Assay
Other
Segment by Application
Gonorrhea
Syphilis
Chlamydia
Herpes Simplex Virus
Human Papillomavirus
Others
Sales by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
Japan
South Korea
India
Australia
Vietnam
Indonesia
Malaysia
Philippines
Singapore
Rest of Asia
Europe
Germany
U.K.
France
Italy
Spain
Benelux
Russia
Rest of Europe
Central and South America
Brazil
Argentina
Rest of South America
Middle East & Africa
GCC Countries
Egypt
Israel
South Africa
Rest of MEA
Chapter Outline
Chapter 1: Defines the Sexually Transmitted Diseases Diagnostics study scope, segments the market by Type and by Application, etc, highlights segment size and growth potential.
Chapter 2: Offers current market state, projects global revenue and sales to 2031, pinpointing high consumption regions and emerging market catalysts
Chapter 3: Dissects the player landscape—ranks by revenue and profitability, details Player performance by product type and evaluates concentration alongside M&A moves.
Chapter 4: Unlocks high margin product segments—compares revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks
Chapter 5: Targets downstream market opportunities—evaluates market size by Application, identifies emerging use cases, and profiles leading customers by region and by Application.
Chapter 6: North America—breaks down market size by Type, by Application and country, profiles key players and assesses growth drivers and barriers.
Chapter 7: Europe—analyses regional market by Type, by Application and players, flagging drivers and barriers.
Chapter 8: Asia Pacific—quantifies market size by Type, by Application, and region/country, profiles top players, and uncovers high potential expansion areas.
Chapter 9: Central & South America—measures market size by Type, by Application, and country, profiles top players, and identifies investment opportunities and challenges.
Chapter 10: Middle East and Africa—evaluates market size by Type, by Application, and country, profiles key players, and outlines investment prospects and market hurdles
Chapter 11: Profiles players in depth—details product specs, revenue, margins; Top-tier players 2024 sales breakdowns by Product type, by Application, by region SWOT analysis, and recent strategic developments.
Chapter 12: Industry chain—analyses upstream, cost drivers, plus downstream channels.
Chapter 13: Market dynamics—explores drivers, restraints, regulatory impacts, and risk mitigation strategies.
Chapter 14: Actionable conclusions and strategic recommendations.
Why This Report:
Beyond standard market data, this analysis provides a clear profitability roadmap—empowering you to:
Allocate capital strategically to high growth regions (Chapters 6–10) and margin rich segments (Chapter 5).
Negotiate from strength with suppliers (Chapter 12) and customers (Chapter 5) using cost and demand intelligence.
Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 3 and 11).
Capitalize on the projected billion‑dollar opportunity with data‑driven regional and segment tactics (Chapter 12-14).
Leverage this 360° intelligence to turn market complexity into actionable competitive advantage.
1 Study Coverage
1.1 Introduction to Sexually Transmitted Diseases Diagnostics: Definition, Properties, and Key Attributes
1.2 Market Segmentation by Type
1.2.1 Global Sexually Transmitted Diseases Diagnostics Market Size by Type, 2020 VS 2024 VS 2031
1.2.2 Cultural and Isolated Organisms
1.2.3 Molecular Test
1.2.4 Immunology Assay
1.2.5 Other
1.3 Market Segmentation by Application
1.3.1 Global Sexually Transmitted Diseases Diagnostics Market Size by Application, 2020 VS 2024 VS 2031
1.3.2 Gonorrhea
1.3.3 Syphilis
1.3.4 Chlamydia
1.3.5 Herpes Simplex Virus
1.3.6 Human Papillomavirus
1.3.7 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Sexually Transmitted Diseases Diagnostics Revenue Estimates and Forecasts 2020-2031
2.2 Global Sexually Transmitted Diseases Diagnostics Revenue by Region
2.2.1 Revenue Comparison: 2020 VS 2024 VS 2031
2.2.2 Historical and Forecasted Revenue by Region (2020-2031)
2.2.3 Global Revenue Market Share by Region (2020-2031)
2.2.4 Emerging Market Focus: Growth Drivers & Investment Trends
3 Competition by Players
3.1 Global Sexually Transmitted Diseases Diagnostics Player Revenue Rankings and Profitability
3.1.1 Global Revenue (Value) by Players (2020-2025)
3.1.2 Global Key Player Revenue Ranking (2023 vs. 2024)
3.1.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)
3.1.4 Gross Margin by Top Player (2020 VS 2024)
3.2 Global Sexually Transmitted Diseases Diagnostics Companies Headquarters and Service Footprint
3.3 Main Product Type Market Size by Players
3.3.1 Cultural and Isolated Organisms Market Size by Players
3.3.2 Molecular Test Market Size by Players
3.3.3 Immunology Assay Market Size by Players
3.3.4 Other Market Size by Players
3.4 Global Sexually Transmitted Diseases Diagnostics Market Concentration and Dynamics
3.4.1 Global Market Concentration (CR5 and HHI)
3.4.2 Entrant/Exit Impact Analysis
3.4.3 Strategic Moves: M&A, Expansion, R&D Investment
4 Global Product Segmentation Analysis
4.1 Global Sexually Transmitted Diseases Diagnostics Revenue Trends by Type
4.1.1 Global Historical and Forecasted Revenue by Type (2020-2031)
4.1.2 Global Revenue Market Share by Type (2020-2031)
4.2 Key Product Attributes and Differentiation
4.3 Subtype Dynamics: Growth Leaders, Profitability and Risk
4.3.1 High-Growth Niches and Adoption Drivers
4.3.2 Profitability Hotspots and Cost Drivers
4.3.3 Substitution Threats
5 Global Downstream Application Analysis
5.1 Global Sexually Transmitted Diseases Diagnostics Revenue by Application
5.1.1 Global Historical and Forecasted Revenue by Application (2020-2031)
5.1.2 Revenue Market Share by Application (2020-2031)
5.1.3 High-Growth Application Identification
5.1.4 Emerging Application Case Studies
5.2 Downstream Customer Analysis
5.2.1 Top Customers by Region
5.2.2 Top Customers by Application
6 North America
6.1 North America Market Size (2020-2031)
6.2 North America Key Players Revenue in 2024
6.3 North America Sexually Transmitted Diseases Diagnostics Market Size by Type (2020-2031)
6.4 North America Sexually Transmitted Diseases Diagnostics Market Size by Application (2020-2031)
6.5 North America Growth Accelerators and Market Barriers
6.6 North America Sexually Transmitted Diseases Diagnostics Market Size by Country
6.6.1 North America Revenue Trends by Country
6.6.2 US
6.6.3 Canada
6.6.4 Mexico
7 Europe
7.1 Europe Market Size (2020-2031)
7.2 Europe Key Players Revenue in 2024
7.3 Europe Sexually Transmitted Diseases Diagnostics Market Size by Type (2020-2031)
7.4 Europe Sexually Transmitted Diseases Diagnostics Market Size by Application (2020-2031)
7.5 Europe Growth Accelerators and Market Barriers
7.6 Europe Sexually Transmitted Diseases Diagnostics Market Size by Country
7.6.1 Europe Revenue Trends by Country
7.6.2 Germany
7.6.3 France
7.6.4 U.K.
7.6.5 Italy
7.6.6 Russia
8 Asia-Pacific
8.1 Asia-Pacific Market Size (2020-2031)
8.2 Asia-Pacific Key Players Revenue in 2024
8.3 Asia-Pacific Sexually Transmitted Diseases Diagnostics Market Size by Type (2020-2031)
8.4 Asia-Pacific Sexually Transmitted Diseases Diagnostics Market Size by Application (2020-2031)
8.5 Asia-Pacific Growth Accelerators and Market Barriers
8.6 Asia-Pacific Sexually Transmitted Diseases Diagnostics Market Size by Region
8.6.1 Asia-Pacific Revenue Trends by Region
8.7 China
8.8 Japan
8.9 South Korea
8.10 Australia
8.11 India
8.12 Southeast Asia
8.12.1 Indonesia
8.12.2 Vietnam
8.12.3 Malaysia
8.12.4 Philippines
8.12.5 Singapore
9 Central and South America
9.1 Central and South America Market Size (2020-2031)
9.2 Central and South America Key Players Revenue in 2024
9.3 Central and South America Sexually Transmitted Diseases Diagnostics Market Size by Type (2020-2031)
9.4 Central and South America Sexually Transmitted Diseases Diagnostics Market Size by Application (2020-2031)
9.5 Central and South America Investment Opportunities and Key Challenges
9.6 Central and South America Sexually Transmitted Diseases Diagnostics Market Size by Country
9.6.1 Central and South America Revenue Trends by Country (2020 VS 2024 VS 2031)
9.6.2 Brazil
9.6.3 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Market Size (2020-2031)
10.2 Middle East and Africa Key Players Revenue in 2024
10.3 Middle East and Africa Sexually Transmitted Diseases Diagnostics Market Size by Type (2020-2031)
10.4 Middle East and Africa Sexually Transmitted Diseases Diagnostics Market Size by Application (2020-2031)
10.5 Middle East and Africa Investment Opportunities and Key Challenges
10.6 Middle East and Africa Sexually Transmitted Diseases Diagnostics Market Size by Country
10.6.1 Middle East and Africa Revenue Trends by Country (2020 VS 2024 VS 2031)
10.6.2 GCC Countries
10.6.3 Israel
10.6.4 Egypt
10.6.5 South Africa
11 Corporate Profile
11.1 Abbott
11.1.1 Abbott Corporation Information
11.1.2 Abbott Business Overview
11.1.3 Abbott Sexually Transmitted Diseases Diagnostics Product Features and Attributes
11.1.4 Abbott Sexually Transmitted Diseases Diagnostics Revenue and Gross Margin (2020-2025)
11.1.5 Abbott Sexually Transmitted Diseases Diagnostics Revenue by Product in 2024
11.1.6 Abbott Sexually Transmitted Diseases Diagnostics Revenue by Application in 2024
11.1.7 Abbott Sexually Transmitted Diseases Diagnostics Revenue by Geographic Area in 2024
11.1.8 Abbott Sexually Transmitted Diseases Diagnostics SWOT Analysis
11.1.9 Abbott Recent Developments
11.2 Thermo Fisher Scientific
11.2.1 Thermo Fisher Scientific Corporation Information
11.2.2 Thermo Fisher Scientific Business Overview
11.2.3 Thermo Fisher Scientific Sexually Transmitted Diseases Diagnostics Product Features and Attributes
11.2.4 Thermo Fisher Scientific Sexually Transmitted Diseases Diagnostics Revenue and Gross Margin (2020-2025)
11.2.5 Thermo Fisher Scientific Sexually Transmitted Diseases Diagnostics Revenue by Product in 2024
11.2.6 Thermo Fisher Scientific Sexually Transmitted Diseases Diagnostics Revenue by Application in 2024
11.2.7 Thermo Fisher Scientific Sexually Transmitted Diseases Diagnostics Revenue by Geographic Area in 2024
11.2.8 Thermo Fisher Scientific Sexually Transmitted Diseases Diagnostics SWOT Analysis
11.2.9 Thermo Fisher Scientific Recent Developments
11.3 CERTEST BIOTEC
11.3.1 CERTEST BIOTEC Corporation Information
11.3.2 CERTEST BIOTEC Business Overview
11.3.3 CERTEST BIOTEC Sexually Transmitted Diseases Diagnostics Product Features and Attributes
11.3.4 CERTEST BIOTEC Sexually Transmitted Diseases Diagnostics Revenue and Gross Margin (2020-2025)
11.3.5 CERTEST BIOTEC Sexually Transmitted Diseases Diagnostics Revenue by Product in 2024
11.3.6 CERTEST BIOTEC Sexually Transmitted Diseases Diagnostics Revenue by Application in 2024
11.3.7 CERTEST BIOTEC Sexually Transmitted Diseases Diagnostics Revenue by Geographic Area in 2024
11.3.8 CERTEST BIOTEC Sexually Transmitted Diseases Diagnostics SWOT Analysis
11.3.9 CERTEST BIOTEC Recent Developments
11.4 OPERON
11.4.1 OPERON Corporation Information
11.4.2 OPERON Business Overview
11.4.3 OPERON Sexually Transmitted Diseases Diagnostics Product Features and Attributes
11.4.4 OPERON Sexually Transmitted Diseases Diagnostics Revenue and Gross Margin (2020-2025)
11.4.5 OPERON Sexually Transmitted Diseases Diagnostics Revenue by Product in 2024
11.4.6 OPERON Sexually Transmitted Diseases Diagnostics Revenue by Application in 2024
11.4.7 OPERON Sexually Transmitted Diseases Diagnostics Revenue by Geographic Area in 2024
11.4.8 OPERON Sexually Transmitted Diseases Diagnostics SWOT Analysis
11.4.9 OPERON Recent Developments
11.5 Roche
11.5.1 Roche Corporation Information
11.5.2 Roche Business Overview
11.5.3 Roche Sexually Transmitted Diseases Diagnostics Product Features and Attributes
11.5.4 Roche Sexually Transmitted Diseases Diagnostics Revenue and Gross Margin (2020-2025)
11.5.5 Roche Sexually Transmitted Diseases Diagnostics Revenue by Product in 2024
11.5.6 Roche Sexually Transmitted Diseases Diagnostics Revenue by Application in 2024
11.5.7 Roche Sexually Transmitted Diseases Diagnostics Revenue by Geographic Area in 2024
11.5.8 Roche Sexually Transmitted Diseases Diagnostics SWOT Analysis
11.5.9 Roche Recent Developments
11.6 Bio-Rad laboratories
11.6.1 Bio-Rad laboratories Corporation Information
11.6.2 Bio-Rad laboratories Business Overview
11.6.3 Bio-Rad laboratories Sexually Transmitted Diseases Diagnostics Product Features and Attributes
11.6.4 Bio-Rad laboratories Sexually Transmitted Diseases Diagnostics Revenue and Gross Margin (2020-2025)
11.6.5 Bio-Rad laboratories Recent Developments
11.7 Qaigen
11.7.1 Qaigen Corporation Information
11.7.2 Qaigen Business Overview
11.7.3 Qaigen Sexually Transmitted Diseases Diagnostics Product Features and Attributes
11.7.4 Qaigen Sexually Transmitted Diseases Diagnostics Revenue and Gross Margin (2020-2025)
11.7.5 Qaigen Recent Developments
11.8 Diasorin SPA
11.8.1 Diasorin SPA Corporation Information
11.8.2 Diasorin SPA Business Overview
11.8.3 Diasorin SPA Sexually Transmitted Diseases Diagnostics Product Features and Attributes
11.8.4 Diasorin SPA Sexually Transmitted Diseases Diagnostics Revenue and Gross Margin (2020-2025)
11.8.5 Diasorin SPA Recent Developments
11.9 MedMira
11.9.1 MedMira Corporation Information
11.9.2 MedMira Business Overview
11.9.3 MedMira Sexually Transmitted Diseases Diagnostics Product Features and Attributes
11.9.4 MedMira Sexually Transmitted Diseases Diagnostics Revenue and Gross Margin (2020-2025)
11.9.5 MedMira Recent Developments
11.10 Hologic
11.10.1 Hologic Corporation Information
11.10.2 Hologic Business Overview
11.10.3 Hologic Sexually Transmitted Diseases Diagnostics Product Features and Attributes
11.10.4 Hologic Sexually Transmitted Diseases Diagnostics Revenue and Gross Margin (2020-2025)
11.10.5 Company Ten Recent Developments
11.11 Cepheid
11.11.1 Cepheid Corporation Information
11.11.2 Cepheid Business Overview
11.11.3 Cepheid Sexually Transmitted Diseases Diagnostics Product Features and Attributes
11.11.4 Cepheid Sexually Transmitted Diseases Diagnostics Revenue and Gross Margin (2020-2025)
11.11.5 Cepheid Recent Developments
11.12 BioMeriuex
11.12.1 BioMeriuex Corporation Information
11.12.2 BioMeriuex Business Overview
11.12.3 BioMeriuex Sexually Transmitted Diseases Diagnostics Product Features and Attributes
11.12.4 BioMeriuex Sexually Transmitted Diseases Diagnostics Revenue and Gross Margin (2020-2025)
11.12.5 BioMeriuex Recent Developments
12 Sexually Transmitted Diseases DiagnosticsIndustry Chain Analysis
12.1 Sexually Transmitted Diseases Diagnostics Industry Chain
12.2 Upstream Analysis
12.2.1 Upstream Key Suppliers
12.3 Middlestream Analysis
12.4 Downstream Sales Model and Distribution Networks
12.4.1 Sales Channels
12.4.2 Distributors
13 Sexually Transmitted Diseases Diagnostics Market Dynamics
13.1 Industry Trends and Evolution
13.2 Market Growth Drivers and Emerging Opportunities
13.3 Market Challenges, Risks, and Restraints
14 Key Findings in the Global Sexually Transmitted Diseases Diagnostics Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Author Details
1.1 Introduction to Sexually Transmitted Diseases Diagnostics: Definition, Properties, and Key Attributes
1.2 Market Segmentation by Type
1.2.1 Global Sexually Transmitted Diseases Diagnostics Market Size by Type, 2020 VS 2024 VS 2031
1.2.2 Cultural and Isolated Organisms
1.2.3 Molecular Test
1.2.4 Immunology Assay
1.2.5 Other
1.3 Market Segmentation by Application
1.3.1 Global Sexually Transmitted Diseases Diagnostics Market Size by Application, 2020 VS 2024 VS 2031
1.3.2 Gonorrhea
1.3.3 Syphilis
1.3.4 Chlamydia
1.3.5 Herpes Simplex Virus
1.3.6 Human Papillomavirus
1.3.7 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Sexually Transmitted Diseases Diagnostics Revenue Estimates and Forecasts 2020-2031
2.2 Global Sexually Transmitted Diseases Diagnostics Revenue by Region
2.2.1 Revenue Comparison: 2020 VS 2024 VS 2031
2.2.2 Historical and Forecasted Revenue by Region (2020-2031)
2.2.3 Global Revenue Market Share by Region (2020-2031)
2.2.4 Emerging Market Focus: Growth Drivers & Investment Trends
3 Competition by Players
3.1 Global Sexually Transmitted Diseases Diagnostics Player Revenue Rankings and Profitability
3.1.1 Global Revenue (Value) by Players (2020-2025)
3.1.2 Global Key Player Revenue Ranking (2023 vs. 2024)
3.1.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)
3.1.4 Gross Margin by Top Player (2020 VS 2024)
3.2 Global Sexually Transmitted Diseases Diagnostics Companies Headquarters and Service Footprint
3.3 Main Product Type Market Size by Players
3.3.1 Cultural and Isolated Organisms Market Size by Players
3.3.2 Molecular Test Market Size by Players
3.3.3 Immunology Assay Market Size by Players
3.3.4 Other Market Size by Players
3.4 Global Sexually Transmitted Diseases Diagnostics Market Concentration and Dynamics
3.4.1 Global Market Concentration (CR5 and HHI)
3.4.2 Entrant/Exit Impact Analysis
3.4.3 Strategic Moves: M&A, Expansion, R&D Investment
4 Global Product Segmentation Analysis
4.1 Global Sexually Transmitted Diseases Diagnostics Revenue Trends by Type
4.1.1 Global Historical and Forecasted Revenue by Type (2020-2031)
4.1.2 Global Revenue Market Share by Type (2020-2031)
4.2 Key Product Attributes and Differentiation
4.3 Subtype Dynamics: Growth Leaders, Profitability and Risk
4.3.1 High-Growth Niches and Adoption Drivers
4.3.2 Profitability Hotspots and Cost Drivers
4.3.3 Substitution Threats
5 Global Downstream Application Analysis
5.1 Global Sexually Transmitted Diseases Diagnostics Revenue by Application
5.1.1 Global Historical and Forecasted Revenue by Application (2020-2031)
5.1.2 Revenue Market Share by Application (2020-2031)
5.1.3 High-Growth Application Identification
5.1.4 Emerging Application Case Studies
5.2 Downstream Customer Analysis
5.2.1 Top Customers by Region
5.2.2 Top Customers by Application
6 North America
6.1 North America Market Size (2020-2031)
6.2 North America Key Players Revenue in 2024
6.3 North America Sexually Transmitted Diseases Diagnostics Market Size by Type (2020-2031)
6.4 North America Sexually Transmitted Diseases Diagnostics Market Size by Application (2020-2031)
6.5 North America Growth Accelerators and Market Barriers
6.6 North America Sexually Transmitted Diseases Diagnostics Market Size by Country
6.6.1 North America Revenue Trends by Country
6.6.2 US
6.6.3 Canada
6.6.4 Mexico
7 Europe
7.1 Europe Market Size (2020-2031)
7.2 Europe Key Players Revenue in 2024
7.3 Europe Sexually Transmitted Diseases Diagnostics Market Size by Type (2020-2031)
7.4 Europe Sexually Transmitted Diseases Diagnostics Market Size by Application (2020-2031)
7.5 Europe Growth Accelerators and Market Barriers
7.6 Europe Sexually Transmitted Diseases Diagnostics Market Size by Country
7.6.1 Europe Revenue Trends by Country
7.6.2 Germany
7.6.3 France
7.6.4 U.K.
7.6.5 Italy
7.6.6 Russia
8 Asia-Pacific
8.1 Asia-Pacific Market Size (2020-2031)
8.2 Asia-Pacific Key Players Revenue in 2024
8.3 Asia-Pacific Sexually Transmitted Diseases Diagnostics Market Size by Type (2020-2031)
8.4 Asia-Pacific Sexually Transmitted Diseases Diagnostics Market Size by Application (2020-2031)
8.5 Asia-Pacific Growth Accelerators and Market Barriers
8.6 Asia-Pacific Sexually Transmitted Diseases Diagnostics Market Size by Region
8.6.1 Asia-Pacific Revenue Trends by Region
8.7 China
8.8 Japan
8.9 South Korea
8.10 Australia
8.11 India
8.12 Southeast Asia
8.12.1 Indonesia
8.12.2 Vietnam
8.12.3 Malaysia
8.12.4 Philippines
8.12.5 Singapore
9 Central and South America
9.1 Central and South America Market Size (2020-2031)
9.2 Central and South America Key Players Revenue in 2024
9.3 Central and South America Sexually Transmitted Diseases Diagnostics Market Size by Type (2020-2031)
9.4 Central and South America Sexually Transmitted Diseases Diagnostics Market Size by Application (2020-2031)
9.5 Central and South America Investment Opportunities and Key Challenges
9.6 Central and South America Sexually Transmitted Diseases Diagnostics Market Size by Country
9.6.1 Central and South America Revenue Trends by Country (2020 VS 2024 VS 2031)
9.6.2 Brazil
9.6.3 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Market Size (2020-2031)
10.2 Middle East and Africa Key Players Revenue in 2024
10.3 Middle East and Africa Sexually Transmitted Diseases Diagnostics Market Size by Type (2020-2031)
10.4 Middle East and Africa Sexually Transmitted Diseases Diagnostics Market Size by Application (2020-2031)
10.5 Middle East and Africa Investment Opportunities and Key Challenges
10.6 Middle East and Africa Sexually Transmitted Diseases Diagnostics Market Size by Country
10.6.1 Middle East and Africa Revenue Trends by Country (2020 VS 2024 VS 2031)
10.6.2 GCC Countries
10.6.3 Israel
10.6.4 Egypt
10.6.5 South Africa
11 Corporate Profile
11.1 Abbott
11.1.1 Abbott Corporation Information
11.1.2 Abbott Business Overview
11.1.3 Abbott Sexually Transmitted Diseases Diagnostics Product Features and Attributes
11.1.4 Abbott Sexually Transmitted Diseases Diagnostics Revenue and Gross Margin (2020-2025)
11.1.5 Abbott Sexually Transmitted Diseases Diagnostics Revenue by Product in 2024
11.1.6 Abbott Sexually Transmitted Diseases Diagnostics Revenue by Application in 2024
11.1.7 Abbott Sexually Transmitted Diseases Diagnostics Revenue by Geographic Area in 2024
11.1.8 Abbott Sexually Transmitted Diseases Diagnostics SWOT Analysis
11.1.9 Abbott Recent Developments
11.2 Thermo Fisher Scientific
11.2.1 Thermo Fisher Scientific Corporation Information
11.2.2 Thermo Fisher Scientific Business Overview
11.2.3 Thermo Fisher Scientific Sexually Transmitted Diseases Diagnostics Product Features and Attributes
11.2.4 Thermo Fisher Scientific Sexually Transmitted Diseases Diagnostics Revenue and Gross Margin (2020-2025)
11.2.5 Thermo Fisher Scientific Sexually Transmitted Diseases Diagnostics Revenue by Product in 2024
11.2.6 Thermo Fisher Scientific Sexually Transmitted Diseases Diagnostics Revenue by Application in 2024
11.2.7 Thermo Fisher Scientific Sexually Transmitted Diseases Diagnostics Revenue by Geographic Area in 2024
11.2.8 Thermo Fisher Scientific Sexually Transmitted Diseases Diagnostics SWOT Analysis
11.2.9 Thermo Fisher Scientific Recent Developments
11.3 CERTEST BIOTEC
11.3.1 CERTEST BIOTEC Corporation Information
11.3.2 CERTEST BIOTEC Business Overview
11.3.3 CERTEST BIOTEC Sexually Transmitted Diseases Diagnostics Product Features and Attributes
11.3.4 CERTEST BIOTEC Sexually Transmitted Diseases Diagnostics Revenue and Gross Margin (2020-2025)
11.3.5 CERTEST BIOTEC Sexually Transmitted Diseases Diagnostics Revenue by Product in 2024
11.3.6 CERTEST BIOTEC Sexually Transmitted Diseases Diagnostics Revenue by Application in 2024
11.3.7 CERTEST BIOTEC Sexually Transmitted Diseases Diagnostics Revenue by Geographic Area in 2024
11.3.8 CERTEST BIOTEC Sexually Transmitted Diseases Diagnostics SWOT Analysis
11.3.9 CERTEST BIOTEC Recent Developments
11.4 OPERON
11.4.1 OPERON Corporation Information
11.4.2 OPERON Business Overview
11.4.3 OPERON Sexually Transmitted Diseases Diagnostics Product Features and Attributes
11.4.4 OPERON Sexually Transmitted Diseases Diagnostics Revenue and Gross Margin (2020-2025)
11.4.5 OPERON Sexually Transmitted Diseases Diagnostics Revenue by Product in 2024
11.4.6 OPERON Sexually Transmitted Diseases Diagnostics Revenue by Application in 2024
11.4.7 OPERON Sexually Transmitted Diseases Diagnostics Revenue by Geographic Area in 2024
11.4.8 OPERON Sexually Transmitted Diseases Diagnostics SWOT Analysis
11.4.9 OPERON Recent Developments
11.5 Roche
11.5.1 Roche Corporation Information
11.5.2 Roche Business Overview
11.5.3 Roche Sexually Transmitted Diseases Diagnostics Product Features and Attributes
11.5.4 Roche Sexually Transmitted Diseases Diagnostics Revenue and Gross Margin (2020-2025)
11.5.5 Roche Sexually Transmitted Diseases Diagnostics Revenue by Product in 2024
11.5.6 Roche Sexually Transmitted Diseases Diagnostics Revenue by Application in 2024
11.5.7 Roche Sexually Transmitted Diseases Diagnostics Revenue by Geographic Area in 2024
11.5.8 Roche Sexually Transmitted Diseases Diagnostics SWOT Analysis
11.5.9 Roche Recent Developments
11.6 Bio-Rad laboratories
11.6.1 Bio-Rad laboratories Corporation Information
11.6.2 Bio-Rad laboratories Business Overview
11.6.3 Bio-Rad laboratories Sexually Transmitted Diseases Diagnostics Product Features and Attributes
11.6.4 Bio-Rad laboratories Sexually Transmitted Diseases Diagnostics Revenue and Gross Margin (2020-2025)
11.6.5 Bio-Rad laboratories Recent Developments
11.7 Qaigen
11.7.1 Qaigen Corporation Information
11.7.2 Qaigen Business Overview
11.7.3 Qaigen Sexually Transmitted Diseases Diagnostics Product Features and Attributes
11.7.4 Qaigen Sexually Transmitted Diseases Diagnostics Revenue and Gross Margin (2020-2025)
11.7.5 Qaigen Recent Developments
11.8 Diasorin SPA
11.8.1 Diasorin SPA Corporation Information
11.8.2 Diasorin SPA Business Overview
11.8.3 Diasorin SPA Sexually Transmitted Diseases Diagnostics Product Features and Attributes
11.8.4 Diasorin SPA Sexually Transmitted Diseases Diagnostics Revenue and Gross Margin (2020-2025)
11.8.5 Diasorin SPA Recent Developments
11.9 MedMira
11.9.1 MedMira Corporation Information
11.9.2 MedMira Business Overview
11.9.3 MedMira Sexually Transmitted Diseases Diagnostics Product Features and Attributes
11.9.4 MedMira Sexually Transmitted Diseases Diagnostics Revenue and Gross Margin (2020-2025)
11.9.5 MedMira Recent Developments
11.10 Hologic
11.10.1 Hologic Corporation Information
11.10.2 Hologic Business Overview
11.10.3 Hologic Sexually Transmitted Diseases Diagnostics Product Features and Attributes
11.10.4 Hologic Sexually Transmitted Diseases Diagnostics Revenue and Gross Margin (2020-2025)
11.10.5 Company Ten Recent Developments
11.11 Cepheid
11.11.1 Cepheid Corporation Information
11.11.2 Cepheid Business Overview
11.11.3 Cepheid Sexually Transmitted Diseases Diagnostics Product Features and Attributes
11.11.4 Cepheid Sexually Transmitted Diseases Diagnostics Revenue and Gross Margin (2020-2025)
11.11.5 Cepheid Recent Developments
11.12 BioMeriuex
11.12.1 BioMeriuex Corporation Information
11.12.2 BioMeriuex Business Overview
11.12.3 BioMeriuex Sexually Transmitted Diseases Diagnostics Product Features and Attributes
11.12.4 BioMeriuex Sexually Transmitted Diseases Diagnostics Revenue and Gross Margin (2020-2025)
11.12.5 BioMeriuex Recent Developments
12 Sexually Transmitted Diseases DiagnosticsIndustry Chain Analysis
12.1 Sexually Transmitted Diseases Diagnostics Industry Chain
12.2 Upstream Analysis
12.2.1 Upstream Key Suppliers
12.3 Middlestream Analysis
12.4 Downstream Sales Model and Distribution Networks
12.4.1 Sales Channels
12.4.2 Distributors
13 Sexually Transmitted Diseases Diagnostics Market Dynamics
13.1 Industry Trends and Evolution
13.2 Market Growth Drivers and Emerging Opportunities
13.3 Market Challenges, Risks, and Restraints
14 Key Findings in the Global Sexually Transmitted Diseases Diagnostics Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Author Details
List of Tables
Table 1. Global Sexually Transmitted Diseases Diagnostics Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Table 2. Global Sexually Transmitted Diseases Diagnostics Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Table 3. Global Sexually Transmitted Diseases Diagnostics Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 4. Global Sexually Transmitted Diseases Diagnostics Revenue by Region (2020-2025) & (US$ Million)
Table 5. Global Sexually Transmitted Diseases Diagnostics Revenue by Region (2026-2031) & (US$ Million)
Table 6. Emerging Market Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 7. Global Sexually Transmitted Diseases Diagnostics Revenue by Players (2020-2025) & (US$ Million)
Table 8. Global Sexually Transmitted Diseases Diagnostics Revenue Market Share by Players (2020-2025)
Table 9. Global Key Players’Ranking Shift (2023 vs. 2024) (Based on Revenue)
Table 10. Global Sexually Transmitted Diseases Diagnostics by Player Tier (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Sexually Transmitted Diseases Diagnostics as of 2024)
Table 11. Global Sexually Transmitted Diseases Diagnostics Average Gross Margin (%) by Player (2020 VS 2024)
Table 12. Global Sexually Transmitted Diseases Diagnostics Companies Headquarters
Table 13. Global Sexually Transmitted Diseases Diagnostics Market Concentration Ratio (CR5 and HHI)
Table 14. Key Market Entrant/Exit (2020-2024) – Drivers & Impact Analysis
Table 15. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
Table 16. Global Sexually Transmitted Diseases Diagnostics Revenue by Type (2020-2025) & (US$ Million)
Table 17. Global Sexually Transmitted Diseases Diagnostics Revenue by Type (2026-2031) & (US$ Million)
Table 18. Key Product Attributes and Differentiation
Table 19. Global Sexually Transmitted Diseases Diagnostics Revenue by Application (2020-2025) & (US$ Million)
Table 20. Global Sexually Transmitted Diseases Diagnostics Revenue by Application (2026-2031) & (US$ Million)
Table 21. Sexually Transmitted Diseases Diagnostics High-Growth Sectors Demand CAGR (2024-2031)
Table 22. Top Customers by Region
Table 23. Top Customers by Application
Table 24. North America Sexually Transmitted Diseases Diagnostics Growth Accelerators and Market Barriers
Table 25. North America Sexually Transmitted Diseases Diagnostics Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 26. Europe Sexually Transmitted Diseases Diagnostics Growth Accelerators and Market Barriers
Table 27. Europe Sexually Transmitted Diseases Diagnostics Revenue Grow Rate (CAGR) by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 28. Asia-Pacific Sexually Transmitted Diseases Diagnostics Growth Accelerators and Market Barriers
Table 29. Asia-Pacific Sexually Transmitted Diseases Diagnostics Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 30. Central and South America Sexually Transmitted Diseases Diagnostics Investment Opportunities and Key Challenges
Table 31. Central and South America Sexually Transmitted Diseases Diagnostics Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 32. Middle East and Africa Sexually Transmitted Diseases Diagnostics Investment Opportunities and Key Challenges
Table 33. Middle East and Africa Sexually Transmitted Diseases Diagnostics Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 34. Abbott Corporation Information
Table 35. Abbott Description and Major Businesses
Table 36. Abbott Product Features and Attributes
Table 37. Abbott Revenue (US$ Million) and Gross Margin (2020-2025)
Table 38. Abbott Revenue Proportion by Product in 2024
Table 39. Abbott Revenue Proportion by Application in 2024
Table 40. Abbott Revenue Proportion by Geographic Area in 2024
Table 41. Abbott Sexually Transmitted Diseases Diagnostics SWOT Analysis
Table 42. Abbott Recent Developments
Table 43. Thermo Fisher Scientific Corporation Information
Table 44. Thermo Fisher Scientific Description and Major Businesses
Table 45. Thermo Fisher Scientific Product Features and Attributes
Table 46. Thermo Fisher Scientific Revenue (US$ Million) and Gross Margin (2020-2025)
Table 47. Thermo Fisher Scientific Revenue Proportion by Product in 2024
Table 48. Thermo Fisher Scientific Revenue Proportion by Application in 2024
Table 49. Thermo Fisher Scientific Revenue Proportion by Geographic Area in 2024
Table 50. Thermo Fisher Scientific Sexually Transmitted Diseases Diagnostics SWOT Analysis
Table 51. Thermo Fisher Scientific Recent Developments
Table 52. CERTEST BIOTEC Corporation Information
Table 53. CERTEST BIOTEC Description and Major Businesses
Table 54. CERTEST BIOTEC Product Features and Attributes
Table 55. CERTEST BIOTEC Revenue (US$ Million) and Gross Margin (2020-2025)
Table 56. CERTEST BIOTEC Revenue Proportion by Product in 2024
Table 57. CERTEST BIOTEC Revenue Proportion by Application in 2024
Table 58. CERTEST BIOTEC Revenue Proportion by Geographic Area in 2024
Table 59. CERTEST BIOTEC Sexually Transmitted Diseases Diagnostics SWOT Analysis
Table 60. CERTEST BIOTEC Recent Developments
Table 61. OPERON Corporation Information
Table 62. OPERON Description and Major Businesses
Table 63. OPERON Product Features and Attributes
Table 64. OPERON Revenue (US$ Million) and Gross Margin (2020-2025)
Table 65. OPERON Revenue Proportion by Product in 2024
Table 66. OPERON Revenue Proportion by Application in 2024
Table 67. OPERON Revenue Proportion by Geographic Area in 2024
Table 68. OPERON Sexually Transmitted Diseases Diagnostics SWOT Analysis
Table 69. OPERON Recent Developments
Table 70. Roche Corporation Information
Table 71. Roche Description and Major Businesses
Table 72. Roche Product Features and Attributes
Table 73. Roche Revenue (US$ Million) and Gross Margin (2020-2025)
Table 74. Roche Revenue Proportion by Product in 2024
Table 75. Roche Revenue Proportion by Application in 2024
Table 76. Roche Revenue Proportion by Geographic Area in 2024
Table 77. Roche Sexually Transmitted Diseases Diagnostics SWOT Analysis
Table 78. Roche Recent Developments
Table 79. Bio-Rad laboratories Corporation Information
Table 80. Bio-Rad laboratories Description and Major Businesses
Table 81. Bio-Rad laboratories Product Features and Attributes
Table 82. Bio-Rad laboratories Revenue (US$ Million) and Gross Margin (2020-2025)
Table 83. Bio-Rad laboratories Recent Developments
Table 84. Qaigen Corporation Information
Table 85. Qaigen Description and Major Businesses
Table 86. Qaigen Product Features and Attributes
Table 87. Qaigen Revenue (US$ Million) and Gross Margin (2020-2025)
Table 88. Qaigen Recent Developments
Table 89. Diasorin SPA Corporation Information
Table 90. Diasorin SPA Description and Major Businesses
Table 91. Diasorin SPA Product Features and Attributes
Table 92. Diasorin SPA Revenue (US$ Million) and Gross Margin (2020-2025)
Table 93. Diasorin SPA Recent Developments
Table 94. MedMira Corporation Information
Table 95. MedMira Description and Major Businesses
Table 96. MedMira Product Features and Attributes
Table 97. MedMira Revenue (US$ Million) and Gross Margin (2020-2025)
Table 98. MedMira Recent Developments
Table 99. Hologic Corporation Information
Table 100. Hologic Description and Major Businesses
Table 101. Hologic Product Features and Attributes
Table 102. Hologic Revenue (US$ Million) and Gross Margin (2020-2025)
Table 103. Hologic Recent Developments
Table 104. Cepheid Corporation Information
Table 105. Cepheid Description and Major Businesses
Table 106. Cepheid Product Features and Attributes
Table 107. Cepheid Revenue (US$ Million) and Gross Margin (2020-2025)
Table 108. Cepheid Recent Developments
Table 109. BioMeriuex Corporation Information
Table 110. BioMeriuex Description and Major Businesses
Table 111. BioMeriuex Product Features and Attributes
Table 112. BioMeriuex Revenue (US$ Million) and Gross Margin (2020-2025)
Table 113. BioMeriuex Recent Developments
Table 114. Raw Materials Key Suppliers
Table 115. Distributors List
Table 116. Market Trends and Market Evolution
Table 117. Market Drivers and Opportunities
Table 118. Market Challenges, Risks, and Restraints
Table 119. Research Programs/Design for This Report
Table 120. Key Data Information from Secondary Sources
Table 121. Key Data Information from Primary Sources
List of Figures
Figure 1. Sexually Transmitted Diseases Diagnostics Product Picture
Figure 2. Global Sexually Transmitted Diseases Diagnostics Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Figure 3. Cultural and Isolated Organisms Product Picture
Figure 4. Molecular Test Product Picture
Figure 5. Immunology Assay Product Picture
Figure 6. Other Product Picture
Figure 7. Global Sexually Transmitted Diseases Diagnostics Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Figure 8. Gonorrhea
Figure 9. Syphilis
Figure 10. Chlamydia
Figure 11. Herpes Simplex Virus
Figure 12. Human Papillomavirus
Figure 13. Others
Figure 14. Sexually Transmitted Diseases Diagnostics Report Years Considered
Figure 15. Global Sexually Transmitted Diseases Diagnostics Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 16. Global Sexually Transmitted Diseases Diagnostics Revenue (2020-2031) & (US$ Million)
Figure 17. Global Sexually Transmitted Diseases Diagnostics Revenue (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Figure 18. Global Sexually Transmitted Diseases Diagnostics Revenue Market Share by Region (2020-2031)
Figure 19. Global Sexually Transmitted Diseases Diagnostics Revenue Market Share Ranking (2024)
Figure 20. Tier Distribution by Revenue Contribution (2020 VS 2024)
Figure 21. Cultural and Isolated Organisms Revenue Market Share by Player in 2024
Figure 22. Molecular Test Revenue Market Share by Player in 2024
Figure 23. Immunology Assay Revenue Market Share by Player in 2024
Figure 24. Other Revenue Market Share by Player in 2024
Figure 25. Global Sexually Transmitted Diseases Diagnostics Revenue Market Share by Type (2020-2031)
Figure 26. Global Sexually Transmitted Diseases Diagnostics Revenue Market Share by Application (2020-2031)
Figure 27. North America Sexually Transmitted Diseases Diagnostics Revenue YoY (2020-2031) & (US$ Million)
Figure 28. North America Top 5 Players Sexually Transmitted Diseases Diagnostics Revenue (US$ Million) in 2024
Figure 29. North America Sexually Transmitted Diseases Diagnostics Revenue (US$ Million) by Type (2020 - 2031)
Figure 30. North America Sexually Transmitted Diseases Diagnostics Revenue (US$ Million) by Application (2020-2031)
Figure 31. US Sexually Transmitted Diseases Diagnostics Revenue (2020-2031) & (US$ Million)
Figure 32. Canada Sexually Transmitted Diseases Diagnostics Revenue (2020-2031) & (US$ Million)
Figure 33. Mexico Sexually Transmitted Diseases Diagnostics Revenue (2020-2031) & (US$ Million)
Figure 34. Europe Sexually Transmitted Diseases Diagnostics Revenue YoY (2020-2031) & (US$ Million)
Figure 35. Europe Top 5 Players Sexually Transmitted Diseases Diagnostics Revenue (US$ Million) in 2024
Figure 36. Europe Sexually Transmitted Diseases Diagnostics Revenue (US$ Million) by Type (2020-2031)
Figure 37. Europe Sexually Transmitted Diseases Diagnostics Revenue (US$ Million) by Application (2020-2031)
Figure 38. Germany Sexually Transmitted Diseases Diagnostics Revenue (2020-2031) & (US$ Million)
Figure 39. France Sexually Transmitted Diseases Diagnostics Revenue (2020-2031) & (US$ Million)
Figure 40. U.K. Sexually Transmitted Diseases Diagnostics Revenue (2020-2031) & (US$ Million)
Figure 41. Italy Sexually Transmitted Diseases Diagnostics Revenue (2020-2031) & (US$ Million)
Figure 42. Russia Sexually Transmitted Diseases Diagnostics Revenue (2020-2031) & (US$ Million)
Figure 43. Asia-Pacific Sexually Transmitted Diseases Diagnostics Revenue YoY (2020-2031) & (US$ Million)
Figure 44. Asia-Pacific Top 8 Players Sexually Transmitted Diseases Diagnostics Revenue (US$ Million) in 2024
Figure 45. Asia-Pacific Sexually Transmitted Diseases Diagnostics Revenue (US$ Million) by Type (2020-2031)
Figure 46. Asia-Pacific Sexually Transmitted Diseases Diagnostics Revenue (US$ Million) by Application (2020-2031)
Figure 47. Indonesia Sexually Transmitted Diseases Diagnostics Revenue (2020-2031) & (US$ Million)
Figure 48. Japan Sexually Transmitted Diseases Diagnostics Revenue (2020-2031) & (US$ Million)
Figure 49. South Korea Sexually Transmitted Diseases Diagnostics Revenue (2020-2031) & (US$ Million)
Figure 50. Australia Sexually Transmitted Diseases Diagnostics Revenue (2020-2031) & (US$ Million)
Figure 51. India Sexually Transmitted Diseases Diagnostics Revenue (2020-2031) & (US$ Million)
Figure 52. Indonesia Sexually Transmitted Diseases Diagnostics Revenue (2020-2031) & (US$ Million)
Figure 53. Vietnam Sexually Transmitted Diseases Diagnostics Revenue (2020-2031) & (US$ Million)
Figure 54. Malaysia Sexually Transmitted Diseases Diagnostics Revenue (2020-2031) & (US$ Million)
Figure 55. Philippines Sexually Transmitted Diseases Diagnostics Revenue (2020-2031) & (US$ Million)
Figure 56. Singapore Sexually Transmitted Diseases Diagnostics Revenue (2020-2031) & (US$ Million)
Figure 57. Central and South America Sexually Transmitted Diseases Diagnostics Revenue YoY (2020-2031) & (US$ Million)
Figure 58. Central and South America Top 5 Players Sexually Transmitted Diseases Diagnostics Revenue (US$ Million) in 2024
Figure 59. Central and South America Sexually Transmitted Diseases Diagnostics Revenue (US$ Million) by Type (2020-2031)
Figure 60. Central and South America Sexually Transmitted Diseases Diagnostics Revenue (US$ Million) by Application (2020-2031)
Figure 61. Brazil Sexually Transmitted Diseases Diagnostics Revenue (2020-2025) & (US$ Million)
Figure 62. Argentina Sexually Transmitted Diseases Diagnostics Revenue (2020-2025) & (US$ Million)
Figure 63. Middle East and Africa Sexually Transmitted Diseases Diagnostics Revenue YoY (2020-2031) & (US$ Million)
Figure 64. Middle East and Africa Top 5 Players Sexually Transmitted Diseases Diagnostics Revenue (US$ Million) in 2024
Figure 65. South America Sexually Transmitted Diseases Diagnostics Revenue (US$ Million) by Type (2020-2031)
Figure 66. Middle East and Africa Sexually Transmitted Diseases Diagnostics Revenue (US$ Million) by Application (2020-2031)
Figure 67. GCC Countries Sexually Transmitted Diseases Diagnostics Revenue (2020-2025) & (US$ Million)
Figure 68. Israel Sexually Transmitted Diseases Diagnostics Revenue (2020-2025) & (US$ Million)
Figure 69. Egypt Sexually Transmitted Diseases Diagnostics Revenue (2020-2025) & (US$ Million)
Figure 70. South Africa Sexually Transmitted Diseases Diagnostics Revenue (2020-2025) & (US$ Million)
Figure 71. Sexually Transmitted Diseases Diagnostics Industry Chain Mapping
Figure 72. Channels of Distribution (Direct Vs Distribution)
Figure 73. Bottom-up and Top-down Approaches for This Report
Figure 74. Data Triangulation
Figure 75. Key Executives Interviewed
Table 1. Global Sexually Transmitted Diseases Diagnostics Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Table 2. Global Sexually Transmitted Diseases Diagnostics Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Table 3. Global Sexually Transmitted Diseases Diagnostics Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 4. Global Sexually Transmitted Diseases Diagnostics Revenue by Region (2020-2025) & (US$ Million)
Table 5. Global Sexually Transmitted Diseases Diagnostics Revenue by Region (2026-2031) & (US$ Million)
Table 6. Emerging Market Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 7. Global Sexually Transmitted Diseases Diagnostics Revenue by Players (2020-2025) & (US$ Million)
Table 8. Global Sexually Transmitted Diseases Diagnostics Revenue Market Share by Players (2020-2025)
Table 9. Global Key Players’Ranking Shift (2023 vs. 2024) (Based on Revenue)
Table 10. Global Sexually Transmitted Diseases Diagnostics by Player Tier (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Sexually Transmitted Diseases Diagnostics as of 2024)
Table 11. Global Sexually Transmitted Diseases Diagnostics Average Gross Margin (%) by Player (2020 VS 2024)
Table 12. Global Sexually Transmitted Diseases Diagnostics Companies Headquarters
Table 13. Global Sexually Transmitted Diseases Diagnostics Market Concentration Ratio (CR5 and HHI)
Table 14. Key Market Entrant/Exit (2020-2024) – Drivers & Impact Analysis
Table 15. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
Table 16. Global Sexually Transmitted Diseases Diagnostics Revenue by Type (2020-2025) & (US$ Million)
Table 17. Global Sexually Transmitted Diseases Diagnostics Revenue by Type (2026-2031) & (US$ Million)
Table 18. Key Product Attributes and Differentiation
Table 19. Global Sexually Transmitted Diseases Diagnostics Revenue by Application (2020-2025) & (US$ Million)
Table 20. Global Sexually Transmitted Diseases Diagnostics Revenue by Application (2026-2031) & (US$ Million)
Table 21. Sexually Transmitted Diseases Diagnostics High-Growth Sectors Demand CAGR (2024-2031)
Table 22. Top Customers by Region
Table 23. Top Customers by Application
Table 24. North America Sexually Transmitted Diseases Diagnostics Growth Accelerators and Market Barriers
Table 25. North America Sexually Transmitted Diseases Diagnostics Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 26. Europe Sexually Transmitted Diseases Diagnostics Growth Accelerators and Market Barriers
Table 27. Europe Sexually Transmitted Diseases Diagnostics Revenue Grow Rate (CAGR) by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 28. Asia-Pacific Sexually Transmitted Diseases Diagnostics Growth Accelerators and Market Barriers
Table 29. Asia-Pacific Sexually Transmitted Diseases Diagnostics Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 30. Central and South America Sexually Transmitted Diseases Diagnostics Investment Opportunities and Key Challenges
Table 31. Central and South America Sexually Transmitted Diseases Diagnostics Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 32. Middle East and Africa Sexually Transmitted Diseases Diagnostics Investment Opportunities and Key Challenges
Table 33. Middle East and Africa Sexually Transmitted Diseases Diagnostics Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 34. Abbott Corporation Information
Table 35. Abbott Description and Major Businesses
Table 36. Abbott Product Features and Attributes
Table 37. Abbott Revenue (US$ Million) and Gross Margin (2020-2025)
Table 38. Abbott Revenue Proportion by Product in 2024
Table 39. Abbott Revenue Proportion by Application in 2024
Table 40. Abbott Revenue Proportion by Geographic Area in 2024
Table 41. Abbott Sexually Transmitted Diseases Diagnostics SWOT Analysis
Table 42. Abbott Recent Developments
Table 43. Thermo Fisher Scientific Corporation Information
Table 44. Thermo Fisher Scientific Description and Major Businesses
Table 45. Thermo Fisher Scientific Product Features and Attributes
Table 46. Thermo Fisher Scientific Revenue (US$ Million) and Gross Margin (2020-2025)
Table 47. Thermo Fisher Scientific Revenue Proportion by Product in 2024
Table 48. Thermo Fisher Scientific Revenue Proportion by Application in 2024
Table 49. Thermo Fisher Scientific Revenue Proportion by Geographic Area in 2024
Table 50. Thermo Fisher Scientific Sexually Transmitted Diseases Diagnostics SWOT Analysis
Table 51. Thermo Fisher Scientific Recent Developments
Table 52. CERTEST BIOTEC Corporation Information
Table 53. CERTEST BIOTEC Description and Major Businesses
Table 54. CERTEST BIOTEC Product Features and Attributes
Table 55. CERTEST BIOTEC Revenue (US$ Million) and Gross Margin (2020-2025)
Table 56. CERTEST BIOTEC Revenue Proportion by Product in 2024
Table 57. CERTEST BIOTEC Revenue Proportion by Application in 2024
Table 58. CERTEST BIOTEC Revenue Proportion by Geographic Area in 2024
Table 59. CERTEST BIOTEC Sexually Transmitted Diseases Diagnostics SWOT Analysis
Table 60. CERTEST BIOTEC Recent Developments
Table 61. OPERON Corporation Information
Table 62. OPERON Description and Major Businesses
Table 63. OPERON Product Features and Attributes
Table 64. OPERON Revenue (US$ Million) and Gross Margin (2020-2025)
Table 65. OPERON Revenue Proportion by Product in 2024
Table 66. OPERON Revenue Proportion by Application in 2024
Table 67. OPERON Revenue Proportion by Geographic Area in 2024
Table 68. OPERON Sexually Transmitted Diseases Diagnostics SWOT Analysis
Table 69. OPERON Recent Developments
Table 70. Roche Corporation Information
Table 71. Roche Description and Major Businesses
Table 72. Roche Product Features and Attributes
Table 73. Roche Revenue (US$ Million) and Gross Margin (2020-2025)
Table 74. Roche Revenue Proportion by Product in 2024
Table 75. Roche Revenue Proportion by Application in 2024
Table 76. Roche Revenue Proportion by Geographic Area in 2024
Table 77. Roche Sexually Transmitted Diseases Diagnostics SWOT Analysis
Table 78. Roche Recent Developments
Table 79. Bio-Rad laboratories Corporation Information
Table 80. Bio-Rad laboratories Description and Major Businesses
Table 81. Bio-Rad laboratories Product Features and Attributes
Table 82. Bio-Rad laboratories Revenue (US$ Million) and Gross Margin (2020-2025)
Table 83. Bio-Rad laboratories Recent Developments
Table 84. Qaigen Corporation Information
Table 85. Qaigen Description and Major Businesses
Table 86. Qaigen Product Features and Attributes
Table 87. Qaigen Revenue (US$ Million) and Gross Margin (2020-2025)
Table 88. Qaigen Recent Developments
Table 89. Diasorin SPA Corporation Information
Table 90. Diasorin SPA Description and Major Businesses
Table 91. Diasorin SPA Product Features and Attributes
Table 92. Diasorin SPA Revenue (US$ Million) and Gross Margin (2020-2025)
Table 93. Diasorin SPA Recent Developments
Table 94. MedMira Corporation Information
Table 95. MedMira Description and Major Businesses
Table 96. MedMira Product Features and Attributes
Table 97. MedMira Revenue (US$ Million) and Gross Margin (2020-2025)
Table 98. MedMira Recent Developments
Table 99. Hologic Corporation Information
Table 100. Hologic Description and Major Businesses
Table 101. Hologic Product Features and Attributes
Table 102. Hologic Revenue (US$ Million) and Gross Margin (2020-2025)
Table 103. Hologic Recent Developments
Table 104. Cepheid Corporation Information
Table 105. Cepheid Description and Major Businesses
Table 106. Cepheid Product Features and Attributes
Table 107. Cepheid Revenue (US$ Million) and Gross Margin (2020-2025)
Table 108. Cepheid Recent Developments
Table 109. BioMeriuex Corporation Information
Table 110. BioMeriuex Description and Major Businesses
Table 111. BioMeriuex Product Features and Attributes
Table 112. BioMeriuex Revenue (US$ Million) and Gross Margin (2020-2025)
Table 113. BioMeriuex Recent Developments
Table 114. Raw Materials Key Suppliers
Table 115. Distributors List
Table 116. Market Trends and Market Evolution
Table 117. Market Drivers and Opportunities
Table 118. Market Challenges, Risks, and Restraints
Table 119. Research Programs/Design for This Report
Table 120. Key Data Information from Secondary Sources
Table 121. Key Data Information from Primary Sources
List of Figures
Figure 1. Sexually Transmitted Diseases Diagnostics Product Picture
Figure 2. Global Sexually Transmitted Diseases Diagnostics Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Figure 3. Cultural and Isolated Organisms Product Picture
Figure 4. Molecular Test Product Picture
Figure 5. Immunology Assay Product Picture
Figure 6. Other Product Picture
Figure 7. Global Sexually Transmitted Diseases Diagnostics Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Figure 8. Gonorrhea
Figure 9. Syphilis
Figure 10. Chlamydia
Figure 11. Herpes Simplex Virus
Figure 12. Human Papillomavirus
Figure 13. Others
Figure 14. Sexually Transmitted Diseases Diagnostics Report Years Considered
Figure 15. Global Sexually Transmitted Diseases Diagnostics Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 16. Global Sexually Transmitted Diseases Diagnostics Revenue (2020-2031) & (US$ Million)
Figure 17. Global Sexually Transmitted Diseases Diagnostics Revenue (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Figure 18. Global Sexually Transmitted Diseases Diagnostics Revenue Market Share by Region (2020-2031)
Figure 19. Global Sexually Transmitted Diseases Diagnostics Revenue Market Share Ranking (2024)
Figure 20. Tier Distribution by Revenue Contribution (2020 VS 2024)
Figure 21. Cultural and Isolated Organisms Revenue Market Share by Player in 2024
Figure 22. Molecular Test Revenue Market Share by Player in 2024
Figure 23. Immunology Assay Revenue Market Share by Player in 2024
Figure 24. Other Revenue Market Share by Player in 2024
Figure 25. Global Sexually Transmitted Diseases Diagnostics Revenue Market Share by Type (2020-2031)
Figure 26. Global Sexually Transmitted Diseases Diagnostics Revenue Market Share by Application (2020-2031)
Figure 27. North America Sexually Transmitted Diseases Diagnostics Revenue YoY (2020-2031) & (US$ Million)
Figure 28. North America Top 5 Players Sexually Transmitted Diseases Diagnostics Revenue (US$ Million) in 2024
Figure 29. North America Sexually Transmitted Diseases Diagnostics Revenue (US$ Million) by Type (2020 - 2031)
Figure 30. North America Sexually Transmitted Diseases Diagnostics Revenue (US$ Million) by Application (2020-2031)
Figure 31. US Sexually Transmitted Diseases Diagnostics Revenue (2020-2031) & (US$ Million)
Figure 32. Canada Sexually Transmitted Diseases Diagnostics Revenue (2020-2031) & (US$ Million)
Figure 33. Mexico Sexually Transmitted Diseases Diagnostics Revenue (2020-2031) & (US$ Million)
Figure 34. Europe Sexually Transmitted Diseases Diagnostics Revenue YoY (2020-2031) & (US$ Million)
Figure 35. Europe Top 5 Players Sexually Transmitted Diseases Diagnostics Revenue (US$ Million) in 2024
Figure 36. Europe Sexually Transmitted Diseases Diagnostics Revenue (US$ Million) by Type (2020-2031)
Figure 37. Europe Sexually Transmitted Diseases Diagnostics Revenue (US$ Million) by Application (2020-2031)
Figure 38. Germany Sexually Transmitted Diseases Diagnostics Revenue (2020-2031) & (US$ Million)
Figure 39. France Sexually Transmitted Diseases Diagnostics Revenue (2020-2031) & (US$ Million)
Figure 40. U.K. Sexually Transmitted Diseases Diagnostics Revenue (2020-2031) & (US$ Million)
Figure 41. Italy Sexually Transmitted Diseases Diagnostics Revenue (2020-2031) & (US$ Million)
Figure 42. Russia Sexually Transmitted Diseases Diagnostics Revenue (2020-2031) & (US$ Million)
Figure 43. Asia-Pacific Sexually Transmitted Diseases Diagnostics Revenue YoY (2020-2031) & (US$ Million)
Figure 44. Asia-Pacific Top 8 Players Sexually Transmitted Diseases Diagnostics Revenue (US$ Million) in 2024
Figure 45. Asia-Pacific Sexually Transmitted Diseases Diagnostics Revenue (US$ Million) by Type (2020-2031)
Figure 46. Asia-Pacific Sexually Transmitted Diseases Diagnostics Revenue (US$ Million) by Application (2020-2031)
Figure 47. Indonesia Sexually Transmitted Diseases Diagnostics Revenue (2020-2031) & (US$ Million)
Figure 48. Japan Sexually Transmitted Diseases Diagnostics Revenue (2020-2031) & (US$ Million)
Figure 49. South Korea Sexually Transmitted Diseases Diagnostics Revenue (2020-2031) & (US$ Million)
Figure 50. Australia Sexually Transmitted Diseases Diagnostics Revenue (2020-2031) & (US$ Million)
Figure 51. India Sexually Transmitted Diseases Diagnostics Revenue (2020-2031) & (US$ Million)
Figure 52. Indonesia Sexually Transmitted Diseases Diagnostics Revenue (2020-2031) & (US$ Million)
Figure 53. Vietnam Sexually Transmitted Diseases Diagnostics Revenue (2020-2031) & (US$ Million)
Figure 54. Malaysia Sexually Transmitted Diseases Diagnostics Revenue (2020-2031) & (US$ Million)
Figure 55. Philippines Sexually Transmitted Diseases Diagnostics Revenue (2020-2031) & (US$ Million)
Figure 56. Singapore Sexually Transmitted Diseases Diagnostics Revenue (2020-2031) & (US$ Million)
Figure 57. Central and South America Sexually Transmitted Diseases Diagnostics Revenue YoY (2020-2031) & (US$ Million)
Figure 58. Central and South America Top 5 Players Sexually Transmitted Diseases Diagnostics Revenue (US$ Million) in 2024
Figure 59. Central and South America Sexually Transmitted Diseases Diagnostics Revenue (US$ Million) by Type (2020-2031)
Figure 60. Central and South America Sexually Transmitted Diseases Diagnostics Revenue (US$ Million) by Application (2020-2031)
Figure 61. Brazil Sexually Transmitted Diseases Diagnostics Revenue (2020-2025) & (US$ Million)
Figure 62. Argentina Sexually Transmitted Diseases Diagnostics Revenue (2020-2025) & (US$ Million)
Figure 63. Middle East and Africa Sexually Transmitted Diseases Diagnostics Revenue YoY (2020-2031) & (US$ Million)
Figure 64. Middle East and Africa Top 5 Players Sexually Transmitted Diseases Diagnostics Revenue (US$ Million) in 2024
Figure 65. South America Sexually Transmitted Diseases Diagnostics Revenue (US$ Million) by Type (2020-2031)
Figure 66. Middle East and Africa Sexually Transmitted Diseases Diagnostics Revenue (US$ Million) by Application (2020-2031)
Figure 67. GCC Countries Sexually Transmitted Diseases Diagnostics Revenue (2020-2025) & (US$ Million)
Figure 68. Israel Sexually Transmitted Diseases Diagnostics Revenue (2020-2025) & (US$ Million)
Figure 69. Egypt Sexually Transmitted Diseases Diagnostics Revenue (2020-2025) & (US$ Million)
Figure 70. South Africa Sexually Transmitted Diseases Diagnostics Revenue (2020-2025) & (US$ Million)
Figure 71. Sexually Transmitted Diseases Diagnostics Industry Chain Mapping
Figure 72. Channels of Distribution (Direct Vs Distribution)
Figure 73. Bottom-up and Top-down Approaches for This Report
Figure 74. Data Triangulation
Figure 75. Key Executives Interviewed
Our team would be happy to assist you with your queries.
About us
Accurate data, The latest market trends, And deeper research directions.
Our sole purpose is to provide a basis for leaders in all walks of life to make more appropriate decisions, to help companies solve existing problems and achieve business goals
Latest reports
Global UV Delayed Curing Adhesives Market Outlook, In‑Depth Analysis & Forecast to 2031
Nov 04, 25
Global Die-Casting Die Steel Market Outlook, In‑Depth Analysis & Forecast to 2031
Nov 04, 25
Global Adaptive Neuromodulation Therapy Devices Market Outlook, In‑Depth Analysis & Forecast to 2031
Nov 04, 25
Useful links
Our Contacts
Room 2306, T6 Fuxing World Financial Center, Kaifu District, Changsha, Hunan, China
(+86) 159 1069 5232